Articles in press

Memory is a fundamental process, regulated by protein–protein interactions within neuronal proteome networks. Learning-dependent changes in specific brain regions important for memory have been detected by mass spectrometry, by comparing proteins from animals trained to learn with mock-trained controls. Detection through this method relies on relative protein abundance; brain dissection is readily available for macroscopic animals to spatially control protein identification by mass spectrometry. In the nematode C. elegans, however, such spatial control is limited due to its microscopic size, hindering its utilization in proteomics. A protocol to address this limitation would strengthen an already excellent model to study memory, given that many proteins for learning are evolutionarily conserved in the worm and single-cell expression is uniquely defined across all 302 neurons. We modified existing protocols to enable (i) proximity labeling detection of neuronal proteins in C. elegans and (ii) high-throughput enrichment of these proteins from >3,000 whole worm bodies simultaneously, to assess trained vs. mock-trained proteomes. This involved the biotin ligase enzyme TurboID, which promiscuously labels nearby proteins with its substrate biotin. Enzyme expression was transgenically restricted to the nervous system, and biotin supplementation was limited to the training (or mock training) period in a classical (gustatory) conditioning paradigm. Labeled proteins were enriched by pull-down using streptavidin, which has a high binding affinity to biotin, and then processed for mass spectrometry runs and qualitative data analysis. This protocol is uniquely advantageous in that it minimizes proteins present before a temporal window of interest (training/mock training), improving the detection of lowly abundant proteins from a specific tissue in the worm (neurons). We have demonstrated that the protocol can sufficiently detect novel learning regulators, thus providing a useful framework to interrogate proteomes in microscopic brains.

The transient receptor mucolipin subtype 1 (TRPML1) is a ubiquitously expressed ion channel involved in lysosomal homeostasis. Recent pharmaceutical interest in developing agonist ligands has emerged due to beneficial effects in neurodegenerative diseases. The major high-throughput screening techniques to investigate this ion channel involve fluorescent calcium imaging and electrophysiology. Despite their high capacity for screening compounds, it is well known that both methods face hurdles, such as the need for expensive, specialized equipment. Here, we present a novel technique to screen for ligands of TRPML1 using a bioluminescence resonance energy transfer (BRET) assay. This assay consists of a target engagement assay in live cells, which permits the determination of binding constants between ligands and the target of interest in equilibrium or time-dependently. We employ a full-length TRPML1 C-terminally tagged with the small bioluminescent protein nanoluciferase. This ensures the correct localization of the ion channel in the lysosomal membrane and an optimal placement of the luciferase in the cytoplasm. We also developed a cell- and lysosome-permeable fluorescent BRET tracer that gives a BRET signal only when bound to the ion channel. This new protocol allows researchers worldwide to screen compounds that would interact with TRPML1 by using any plate reader with luminescent and fluorescence filters.

Multiple sclerosis (MS) is a chronic autoimmune disease characterized primarily by inflammatory demyelination of the central nervous system and is one of the leading causes of non-traumatic neurological disability in young and middle-aged adults worldwide. Myelin loss leads to impaired neural conduction, while progressive axonal degeneration resulting from failed remyelination constitutes a major pathological basis for irreversible disability in patients. Among currently approved treatments for MS, effective therapies that directly promote remyelination are still lacking; therefore, establishing animal models that can precisely recapitulate the myelin injury-repair process is essential for elucidating the mechanisms of remyelination and screening remyelination-promoting drugs. Focal demyelination models are important tools for investigating the mechanisms of remyelination and for developing therapeutic strategies for demyelinating diseases such as multiple sclerosis. Unlike the inflammation-driven injury of the experimental autoimmune encephalomyelitis (EAE) model and the systemic metabolic toxicity-induced demyelination of the cuprizone model, the lysophosphatidylcholine (LPC) injection model directly disrupts myelin in the corpus callosum through local injection of a membrane-solubilizing lipid, inducing focal demyelinating lesions and enabling investigators to study, in a controlled manner, the recruitment and differentiation of oligodendrocyte progenitor cells as well as the dynamic process of remyelination. This protocol describes the complete workflow for establishing focal demyelinating lesions by stereotaxic injection of LPC into the mouse corpus callosum, covering surgical preparation, coordinate localization, controlled injection, and postoperative care. Compared with existing methods, its main advantages lie in the precise control of the lesion and the synchronization of the post-injury repair phase, making it highly suitable for quantitative comparisons. Beyond the corpus callosum, this method is also broadly applicable to focal demyelination studies in other white matter tracts (including the spinal cord, optic nerve, and others), serving as a versatile platform for investigating region-specific myelin injury and repair.

Cytoplasmic protein aggregation is a defining feature of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Huntington’s disease, and certain forms of motor neuron disease. Recent evidence indicates that promyelocytic leukemia protein (PML) and engineered PML-derived variants can act as versatile aggregate-remodeling factors. In particular, cytoplasmically redirected PML variants recognize pathological cytoplasmic inclusions and promote their clearance. Here, we describe a protocol to generate and validate two engineered cytoplasmic PML variants: full-length mPML, which is redirected to the cytoplasm by disruption of its nuclear localization sequence, and the truncated mPML^ΔRBC variant, which lacks the RING, B-box, and coiled-coil domain but retains aggregate-reducing activity. The protocol integrates fluorescence-based imaging, bimolecular fluorescence complementation, detergent-soluble/insoluble fractionation, and validation in primary rat cortical neurons. This workflow provides a practical platform for assessing cytoplasmic aggregate burden and for comparing the aggregate-remodeling activities of PML-derived constructs. It can also be adapted to other disease-associated aggregation-prone proteins, including TDP-43, SOD1, FUS, tau, polyGA, and polyQ-expanded proteins.

ADP ribosylation (ADPr) is a crucial post-translational modification that plays a vital role in DNA damage repair. Catalyzed by ADP ribose polymerases using NAD⁺ as a substrate, ADPr activates DNA repair pathways rapidly, thereby maintaining genomic integrity. The involvement of ADP ribose hydrolases in this process is significant, as they hydrolyze PAR chains, facilitating the release of ADPr-modified proteins from DNA or other proteins, which is essential for subsequent DNA repair steps. This protocol outlines a high-throughput screening method for identifying inhibitors of ADP ribose hydrolases, utilizing His-Tb-conjugated and ADPr-modified His-ADP ribose polymerase as the signal donor, and GST-d2-conjugated GST-XRCC1 as the signal receptor. The detection of time-resolved fluorescence signals enables efficient evaluation of compounds with potential therapeutic activity against cancer.

Immunohistochemistry (IHC) is a highly specific and widely used laboratory technique for assessing protein localization and expression in tissue samples. Interpretation of 3,3’ diamino benzidine (DAB)-based IHC is often based on observer-dependent manual scoring or traditional imaging software, which may show variability in DAB staining quantification. Furthermore, conventional image analysis tools often face limitations in precisely defining cell boundaries and quantifying membrane-specific signals. In this study, we present a standardized image analysis workflow using CellProfiler, an open-source software for image analysis for the quantification of membrane staining intensity in IHC images captured from slides prepared using formalin-fixed paraffin-embedded (FFPE) human cervical cancer tissue sections. The image analysis workflow was demonstrated using ASCT2 (SLC1A5), a membrane-localized amino acid transporter, as a representative biomarker for membrane-associated protein expression. This protocol involves image preprocessing, object identification, segmentation, and intensity measurement modules to distinguish cell membranes from cytoplasmic regions, enabling automated quantification of membrane intensity signals. The CellProfiler pipeline demonstrated improved accuracy in cell boundary identification and quantification of membrane-specific staining intensity. This is a rapid quantification process, since processing of each image only takes a few seconds; therefore, the analysis for 100 images can be performed within 10–15 min. This segmentation and quantification strategy is applicable to other membrane-based biomarkers after appropriate optimization of segmentation parameters. Following further minor modifications to the object identification modules, this pipeline can be used to detect and quantify cytoplasm- or nuclei-localized DAB-IHC markers across different tissue types. Overall, this protocol provides a standardized, user-friendly, and reproducible workflow for quantitative IHC image analysis that can be broadly applied to the study of protein biomarkers of different localizations, such as nuclei, cytoplasm, and cell membranes from different tissue types.

Antibody (Ab) and nanobody (Nb) humanization is essential for reducing immunogenicity in therapeutic applications. HuDiff is an adaptive autoregressive diffusion approach that generates humanized antibodies and nanobodies from scratch using only complementarity-determining region sequences as input, eliminating the need for preexisting human templates. The method follows a two-stage training pipeline: pretraining on human antibody sequences to learn framework region patterns, followed by fine-tuning on target-species sequences. HuDiff-Ab processes paired heavy and light chains for conventional antibodies, while HuDiff-Nb can incorporate a specialized inpainting mode to preserve critical nanobody framework residues. This protocol provides a complete step-by-step guide for implementing HuDiff, covering data preparation, model training, and sequence generation.

Nucleases are key tools in molecular biology, enabling controlled nucleic acid digestion for applications such as ribosome profiling. Micrococcal nuclease (MNase) from Staphylococcus aureus is widely used as a tool in molecular biology and biochemistry, but its reduced activity under high-salt conditions necessitates higher enzyme input to achieve efficient digestion, increasing costs in studies of halophilic organisms. Here, we present an optimized protocol for the heterologous expression and purification of the recombinant staphylococcal MNase. The procedure enables reproducible production of a highly active, stable enzyme and incorporates an enzymatic activity assay to standardize batches to minimize variability. The resulting MNase exhibits robust activity in high-salt environments and remains stable during storage, providing a cost-effective and reliable alternative to commercial nucleases for ribosome profiling and related applications.

Isogenic populations of Saccharomyces cerevisiae exhibit significant proliferative heterogeneity, with individual cells within a clonal culture displaying divergent growth rates and metabolic states. Investigating the origins of this variation requires a method to reconstruct the individual histories of cells within the population. This protocol describes a method for single-cell microencapsulation in alginate microspheres to create a physically stable, traceable, three-dimensional genealogical environment. By utilizing the alginate matrix to prevent daughter cell migration, the replicative history of a founder cell can be mathematically reconstructed. This is achieved by correlating the total cell count (N) within a developed microcolony with the total number of accumulated bud scars (n) visualized via confocal microscopy.

Bacterial cellulose (BC) is a renewable biopolymer valued for its exceptional purity, biocompatibility, and mechanical strength, with broad applications in biomedicine and sustainable materials. However, achieving reproducible BC production and downstream processing remains a major challenge. Inoculum preparation is particularly difficult to standardize because cellulose-producing strains form pellicles that sequester cells, making optical density measurements unreliable. In addition, recovery and drying procedures can alter fiber accessibility, and enzymatic hydrolysis conditions are often inconsistently defined and lack proper enzyme activity assessment. These issues contribute to substantial variability in BC-derived nanoparticle yields. This protocol describes the production of BC from Komagataeibacter xylinus DSMZ 6513, including culture medium preparation, inoculum generation, and scaling up under static cultivation conditions. It further details BC pellicle purification using NaOH, followed by pulping, freeze-drying, and milling to ensure material stability during storage and use. BC hydrolysis is performed with commercially available cellulase from Trichoderma reesei, with enzyme activity quantified prior to each reaction to ensure reproducibility. This standardized approach enables the reproducible production of bacterial cellulose nanoparticles (BCNPs). The protocol also includes minimal morphological characterization methods. By standardizing culture, recovery, and hydrolysis steps, the workflow reduces experimental variability and improves comparability across laboratories. Overall, it provides an accessible and reproducible method for generating BC and BCNPs of consistent quality without the need for specialized instrumentation.

Identifying substrates of protein phosphatases has been technically challenging and has hampered progress in the field of plant sciences. Small molecule inhibitors of protein phosphatases have aided in uncovering classes of phosphatases that target substrates, but that too has severe limitations. Here, we describe a method that enriches phosphorylated substrates using TiO₂ and phospho-tyrosine antibodies in phosphatase knockout lines of Arabidopsis thaliana. When compared to wild-type plants, this approach permits identification of putative substrates and specific phosphorylation sites by mass spectrometry, allowing for further in vitro or functional validation. The key to the approach described here is the use of phosphatase knockout lines to maintain substrates in a phosphorylated state and using phospho-tyrosine antibodies to enrich for tyrosine phosphorylated peptides.

Gastric cancer remains a major global health challenge, and reliable prognostic biomarkers are urgently needed to guide treatment decisions. Here, we present a simple and efficient protocol for a novel liquid biopsy approach based on quantifying gastric fluid DNA (gfDNA) collected during routine esophagogastroduodenoscopy (EGD). We have previously shown that gfDNA carries gastric cancer–derived mutations; moreover, its concentration increases with tumor progression and varies according to cancer prognosis. This empirically observed increase in gfDNA may mechanistically stem from enhanced cellular turnover, tissue disorganization, dysbiosis of the local microbiota, and/or fluctuations in immune cell infiltrates. Surprisingly, however, in patients diagnosed with gastric cancer, elevated gfDNA levels were also associated with improved survival. This paradoxical finding may be reconciled by an increased anti-tumor immune cell response in treatment-responsive gastric cancers, as well as by the contribution of non-tumoral DNA from inflammatory processes within the microenvironment of the stomach. Here, we detail a standardized protocol for gastric fluid collection and processing, designed to support downstream gfDNA quantification among other potential molecular applications.

Limb development requires the coordination of multiple cell types, including the limb bud mesoderm and surface ectoderm, by the apical ectodermal ridge (AER), a specialized signaling center secreting numerous morphogens. Characterizing these cell–cell interactions is crucial for understanding limb morphogenesis, but they are challenging to study in vivo. Furthermore, existing in vitro models do not capture the multilineage complexity of the limb. We recently developed a robust 7-day differentiation protocol using mouse embryonic stem cells (mESCs) to generate heterogeneous cultures containing cells with characteristics of the limb bud mesoderm, surface ectoderm, and AER. Dissociating and reaggregating these cultures in low attachment 96-well plates forms budoids, organoids that display certain limb bud–like features. Budoids undergo chondrogenesis-mediated symmetry breaking and elongation within 5 days of culture. Altogether, our protocols have enabled the study of cell–cell interactions in limb development and provide an easily scalable model adaptable for various applications, including drug testing and congenital disorder modeling.

RNA modifications and their “writer,” “eraser,” and “reader” proteins are emerging as key regulators of gene expression and DNA repair through dynamically regulating RNA:DNA hybrids, or R-loops, during transcription. Therefore, it is paramount to develop rigorous techniques for accurate analysis of R-loop modifications. A convenient method for analyzing RNA modifications within total RNA is by dot blot with specific RNA modification antibodies; however, analysis of the modification of the RNA moiety within R-loops presents specific challenges. Here, we provide a detailed protocol for the production or purification of DNA containing R-loops in vitro and from cells, and the analysis of the RNA moiety modifications by dot blot. The DNA containing R-loops is treated with either mock or RNase H, which specifically degrades the RNA within RNA:DNA hybrids, to control for the specificity of the signal as originating from R-loops. Known quantities of the mock or RNase H–treated DNA are then spotted on three membranes, each blotted with antibodies that recognize double-stranded DNA, RNA:DNA hybrids, or the specific RNA modification antibodies of interest, such as m⁶A or ac⁴C. Thus, this protocol is useful to both biochemists and cell biologists with scientific interests at the intersection of R-loops and epitranscriptomics.

Mycoparasitism is an important mechanism of fungal antagonism in which one fungus parasitizes another. This type of interaction plays a major role in the biocontrol activity of Trichoderma spp. against phytopathogenic fungi. Detailed visualization of these interactions is essential for understanding the structural mechanisms involved in fungal antagonism, including hyphal attachment, coiling, penetration, and cellular distortion. Scanning electron microscopy (SEM) is widely used for structural examination of fungal interactions; however, conventional preparation methods such as filter paper systems, membrane overlays, and agar block techniques often result in structural distortion, fragile sample handling, and difficulty in locating defined interaction zones. Here, we describe a modified slide-embedded technique for SEM visualization of mycoparasitic interactions between filamentous fungi. The protocol is adapted from previously reported slide culture approaches and involves embedding pre-cut sterile glass slide fragments directly into potato dextrose agar (PDA), followed by sequential inoculation of Fusarium sp. and Trichoderma viride. Fungal interactions occurring directly on the glass surface are subsequently subjected to fixation with 2.5% glutaraldehyde, graded ethanol dehydration, sputter coating, and SEM observation. Compared with conventional methods, the present approach provides improved handling stability, better preservation of native hyphal architecture, reduced deformation during processing, and easier localization of interaction zones during microscopy. The protocol also enables clear visualization of early antagonistic events such as hyphal coiling, penetration, and surface colonization. Due to its simplicity, reproducibility, and minimal technical complexity, this method serves as a practical and efficient approach for SEM-based investigation of fungal–fungal interactions and can be readily adapted for studying diverse mycoparasitic systems.

Chromatin modifications regulate genome function by recruiting proteins that control transcription, genome organization, and DNA repair. Identifying the proteins associated with specific chromatin modifications is therefore essential for understanding how these regulatory processes operate. Traditional approaches, including chromatin immunoprecipitation and affinity purification coupled to mass spectrometry, have uncovered many chromatin-associated proteins. However, they often rely on crosslinking and chromatin fragmentation, which can disrupt native chromatin architecture and limit the detection of transient interactions. Here, we describe a proximity-labeling protocol for identifying the chromatin-dependent protein interactome associated with specific chromatin marks, termed ChromID. ChromID uses engineered chromatin readers (eCRs) fused to a promiscuous biotin ligase, which labels proteins in the immediate vicinity of the targeted chromatin mark. The protocol includes in vivo biotin labeling, nuclear extract preparation, streptavidin-based enrichment, and tryptic digestion for downstream LC-MS/MS analysis. The protocol has been validated across multiple cell types and chromatin contexts and can be extended to other chromatin-associated proteins, providing a versatile approach to profile chromatin-associated proteomes within their native cellular environment.

Riboswitches are structured non-coding RNA elements that regulate gene expression in response to small molecules; they serve as valuable systems in both public health and biophysical research by elucidating principles around RNA–ligand interactions, structure, and cellular function. Traditional approaches to studying riboswitches have relied on low-throughput techniques such as reporter assays or gel electrophoresis analysis of transcriptional products, which are limited in scalability. In this study, we present a high-throughput protocol to characterize the transcriptional activity of nearly 2,000 natural variants of the fluoride riboswitch in in vitro transcription. Starting with bioinformatics, we compiled a comprehensive dataset of riboswitch variants and then employed massive parallel oligonucleotide synthesis to generate an oligo pool of the riboswitch library. This pool was transcribed in vitro, converted into an Illumina-compatible next-generation sequencing (NGS) library, and analyzed to identify transcriptionally active riboswitch candidates. The workflow integrates natural riboswitch bioinformatic acquisition into a quantitative readout in a single streamlined pipeline, enabling large-scale exploration of transcriptional riboswitch function. This protocol offers a scalable method for mapping genotype-to-function relationships across transcriptional riboswitch families, accelerating the identification of functional variants for desired applications.

Most existing preclinical models have been limited in their predictive value to mimic patients’ responses, which is a major drawback in drug development and the identification of predictive biomarkers. To overcome these limitations, patient-derived three-dimensional in vitro models have been proposed. One of them is the organoid model, which preserves the original cellular heterogeneity and recapitulates epithelial architecture and functionality. Recently, studies using patient-derived organoids for drug screening applications have increased in quantity, and organoids have already been applied to pancreatic, colon, and lung cancers and female gynecological malignancies. Here, we established a multiplex workflow to analyze longitudinal therapeutic effects of anti-cancer therapeutics on organoid growth, viability, and cytotoxicity by combining state-of-the-art viability measurement with automated live cell imaging. This workflow can be used for the prediction of patient-specific treatment response, high-throughput screening of potential anticancer drugs, and downstream analysis to identify novel therapeutic targets.

Accurate, sensitive quantification of B-lineage cells is critical for pharmacodynamic evaluation of B cell–targeted therapies in lupus nephritis (LN) clinical trials. While high-dimensional discovery platforms offer broad profiling, they often lack the sensitivity, quantitative rigor, and throughput needed for precise cell enumeration in renal trial needle biopsies. Traditional immunostaining is hampered by CD20-directed therapeutic masking or downregulation, inadequate sensitivity of CD19 in FFPE tissue, and confounding renal tubular CD138 expression. This protocol details an automated, fit-for-purpose, 5-plex sequential tyramide signal amplification (TSA)-based immunofluorescence assay (CD38, CD79a, CD19, Ki-67, CD138) developed on the Ventana Discovery Ultra platform for deployment on single tissue sections. The workflow anchors B-cell detection on CD79a to ensure sensitivity and utilizes CD38 as an obligate co-marker for CD138+ antibody-secreting cells (ASCs) to definitively exclude the CD138+ epithelial background. Following acquisition via fluorescence whole-slide imaging, a digital analysis pipeline utilizing InstanSeg-based automated segmentation rigorously classifies cell phenotypes to generate precise spatial densities (cells/mm²). This validated protocol maximizes data yield from scarce clinical biopsies while providing high-precision quantitative monitoring of longitudinal therapeutic depletion in the renal microenvironment.

Amyotrophic lateral sclerosis (ALS) is characterized by early and spatially restricted pathology in motor axons, including distal degeneration and accumulation of aggregation-prone proteins such as TDP-43. However, a major limitation in the field has been the lack of approaches that enable robust, quantitative, and compartment-specific analysis of these early axonal events, particularly in human-relevant systems. Here, we describe an integrated experimental and analytical framework that enables quantitative dissection of axonal degeneration and protein aggregation, specifically within distal motor axons. By combining compartmentalized human co-cultures with a dedicated image analysis strategy, this approach enables selective and quantitative analysis of pathological processes specifically within axons, independent of surrounding tissues such as muscle and other cellular compartments. This framework captures both structural degeneration and protein aggregation dynamics at subcellular resolution, enabling spatially resolved quantitative analysis of disease-relevant changes along axons. Importantly, the analytical framework is not limited to TDP-43 but is broadly applicable to diverse aggregation-prone proteins, thereby providing a generalizable platform to study axonal pathology across neurodegenerative diseases. Together, this work provides a scalable approach for investigating axonal pathology as an early and measurable feature of neurodegeneration, with potential applications in mechanistic studies and therapeutic targeting in ALS and related disorders.

Actin filaments undergo dynamic growth and disassembly at their ends, regulated by many actin-binding proteins. However, structural analysis of filament end dynamics has been challenging due to the low abundance of filament ends in cryo-electron microscopy (cryo-EM) micrographs, their intrinsic polymorphisms, and the diversity and flexibility of end-binding proteins. Here, we describe a standardized cryo-EM protocol for determining actin filament end structures. First, short actin filaments are generated either biochemically using capping or severing proteins or mechanically through shearing. Filaments are then vitrified under conditions optimized for each specific end-binding protein. We describe data collection parameters using a 300 kV Titan Krios G3i microscope, including optimized grid preparation and imaging settings. Finally, we present a data processing pipeline for filament end structure determination based on machine learning–based particle picking, masking, and sorting strategies. This protocol has enabled the determination of multiple high-resolution structures of free, capped, elongating, and depolymerizing actin filament ends, and we further discuss considerations for extending this approach to other end-binding proteins.

Genetically encodable reporters that produce signals detectable in deep tissues offer a powerful tool for noninvasive monitoring of molecular events in vivo. Although magnetic resonance imaging (MRI) is a standard technique for noninvasive clinical imaging, its wider application in detecting molecular activities has been constrained by the lack of programmable sensors. This limitation is in stark contrast to the widespread use of fluorescent reporter–derived sensors in cultured cells and in transparent specimens. To overcome this limitation, we recently developed the modular aquaporin-based protease-activatable probe for enhanced reporting (MAPPER) platform. This sensor engineering framework integrates a metal-free MRI reporter derived from human aquaporin-1 (hAqp1) with synthetic protease-based circuits. This integration facilitates the modular and scalable creation of a wide range of sensors by regulating protease activity through precise molecular events, such as protein–protein interactions, pharmacological inhibition, and second messenger signaling. In this paper, we present a detailed protocol for constructing and deploying sensors using the MAPPER paradigm. The protocol encompasses genetic design, lentiviral production, stable cell line generation, biochemical and microscopic validation of sensor function, diffusion-weighted MRI, and MR image analysis to quantify sensor signals in terms of the apparent diffusion coefficient. We describe two distinct MAPPER architectures: DD-MAPPER, which leverages protease-controlled protein degradation, and ER-MAPPER, which utilizes protease-controlled, subcellular trafficking. The MAPPER framework allows adaptation to various molecular targets without the need to redesign the core MRI reporter mechanism, making MAPPER a versatile platform for noninvasive biosensing in living cells and tissues.

CRISPR-Cas9 barcoding technologies enable cells to record molecular events as permanent genetic changes that can be read out retrospectively. This protocol describes the implementation of a CRISPR-based recording system that gradually accumulates mutations over extended periods and is compatible with standard single-cell RNA sequencing (scRNA-seq) workflows. By temporally regulating CRISPR activity, the system generates mutational barcodes that can be captured together with individual cell transcriptomes. These barcodes are subsequently decoded using computational reconstruction approaches to infer temporal information, enabling the joint analysis of cellular states and time-resolved molecular histories. This approach provides a single-cell-compatible framework for studying dynamic biological processes in heterogeneous mouse embryonic stem cell (mESC)-derived systems, with potential extension to other biological systems.